Role of soluble upar in the pathogenesis of proteinuric kidney disease
AssigneesUniversity of Miami Office of Technology Transfer, The General Hospital Corporation d/b/a Massachusetts General Hospital
InventorJochen Reiser
Life of this patent
Estimating the term…
Abstract
Compositions which specifically block urokinase receptor (uPAR) in podocytes; compositions which modulate or block soluble urokinase receptor (suPAR); compositions which modulate pathways in which uPAR is associated with, protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions.
Claims28
A method of treating renal diseases or disorders, comprising administering to a patient in need thereof, an effective amount of an agent which inhibits soluble urokinase receptor (suPAR) activity and/or function and/or modulates expression soluble and/or membrane bound urokinase receptor (uPAR) and/or pathways associated with urokinase receptor hi vivo and,
- treating renal diseases or disorders.
A method of identifying agents which modulate soluble urokinase receptor, function and/or activity in vivo comprising:
- contacting the soluble urokinase receptor with one or more agents;
- measuring physical or chemical changes in the soluble urokinase receptor molecule;
- and,
- identifying agents which modulate the uPAR-L expression, function and/or activity in vivo.
A method of identifying agents which modulate soluble urokinase receptor molecules (suPAR) expression, function and/or activity comprising:
- culturing a kidney cell or kidney cell line;
- contacting said cells with one or more agents;
- measuring the suPAR, expression, function, or activity;
- and,
- identifying agents which modulate soluble urokinase receptor molecules (suPAR), expression, function and/or activity.
A composition comprising a pharmaceutical composition and/or one or more soluble urokinase receptor molecule (suPAR) inhibitors and/or agents which inhibit decreases soluble urokinase receptor molecule (suPAR) expression, function, and/or activity in a therapeutically effective amount.
A biomarker for the diagnosis of a disease or disorder characterized by proteinuria and/or identification of individuals at risk of developing a disease or disorder characterized by proteinuria comprising:
- soluble or membrane bound urokinase receptor molecule (suPAR), variants, mutants or fragments thereof.
An antibody or aptamer specific for urokinase receptor (suPAR), mutants, variants, fragments, derivatives or analogs thereof.
An assay for measuring soluble urokinase receptor (suPAR) in patients comprising:
- contacting a biological sample from a patient with a detectably labeled anti-suPAR antibody;
- and,
- measuring soluble urokinase receptor (suPAR) in patients.
A method of diagnosing a patient with kidney disease, comprising detecting in a patient or patient sample soluble uPAR;
- correlating the amounts of suPAR in the patient or patient sample with kidney disease or podocyte effacement;
- and,
- diagnosing a patient with kidney disease.
Dependencies are inferred from the claim text.